Methotrexate for alopecia areata: A systematic review and meta-analysis - 13/12/18
Abstract |
Background |
Methotrexate has been used both as monotherapy and as an adjunct to corticosteroids in the treatment of alopecia areata (AA), though there exists a paucity of definitive evidence and guidelines in this setting.
Objectives |
To 1) determine the efficacy and risks associated with methotrexate therapy for AA, 2) determine the differences in efficacy of combination (methotrexate plus corticosteroids) versus stand-alone (methotrexate) treatment, and 3) determine the relative efficacy of methotrexate in adult versus pediatric populations.
Methods |
A systematic review and meta-analysis was performed according to recommended PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses] guidelines.
Results |
Methotrexate has reasonable effectiveness in patients with severe AA; adults appear to be more responsive to methotrexate treatment than pediatric patients. Combination treatment results in a higher complete response rate than methotrexate stand-alone treatment. A large proportion of patients had recurrence in the setting of tapering treatment. Complication rates were acceptable and similar between adult and pediatric patients.
Limitations |
The studies reviewed were retrospective observational studies with heterogeneity between centers in terms of methotrexate dosages and protocols in use for AA, and there was a lack of data beyond 1 year for the adjunctive treatments.
Conclusion |
Methotrexate is an effective monotherapy or adjunct therapy in combination with corticosteroids in the treatment of severe AA.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, alopecia areata, dermatology, meta-analysis, methotrexate, systematic review
Abbreviations used : AA, CI
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
Vol 80 - N° 1
P. 120 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?